Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Abstract: An electrical receptacle connector includes a terminal module assembly and a grounding collar thereon. The terminal module assembly includes the front mating tongue, the rear body, and the step structure therebetween, and the corresponding contacts. The contacts are secured to the body with contacting sections exposed upon the mating tongue. The grounding collar includes the grounding regions located on two opposite upper and lower surfaces of the step structure. The front edge area of the grounding region adjacent to the front edge area, forms a notch so as to leave a space to allow the spring finger of the corresponding interior grounding plate of the plug connector to first slide upon the step structure and successively contact the grounding region of the grounding collar of the receptacle connector.

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Abstract: An electrical connector includes a contact module comprising two rows of contacts retained therein and a shielding plate, the contacts module defining a main base, a middle step and a mating tongue and, the middle step being located between the main base and the mating tongue in a mating direction, the contacts comprising contacting portions exposed on opposite surfaces of the mating tongue; a metallic shell retained on the main base and surrounding the mating tongue and the middle step to define a mating cavity thereamong and a one piece grounding collar. The grounding collar includes a collar portion fitly surrounding the middle step and a grounding plate extending from the collar portion to mechanically and electrically connect with the metallic shell.

Abstract: An electrical receptacle connector includes a terminal module assembly and a grounding collar thereon. The terminal module assembly includes the front mating tongue, the rear body, and the step structure therebetween, and the corresponding contacts. The contacts are secured to the body with contacting sections exposed upon the mating tongue. The grounding collar includes the grounding regions located on two opposite upper and lower surfaces of the step structure. The front edge area of the grounding region adjacent to the front edge area, forms a notch so as to leave a space to allow the spring finger of the corresponding interior grounding plate of the plug connector to first slide upon the step structure and successively contact the grounding region of the grounding collar of the receptacle connector.

Abstract: An electrical connector includes a contact module comprising two rows of contacts retained therein and a shielding plate, the contacts module defining a main base, a middle step and a mating tongue and, the middle step being located between the main base and the mating tongue in a mating direction, the contacts comprising contacting portions exposed on opposite surfaces of the mating tongue; a metallic shell retained on the main base and surrounding the mating tongue and the middle step to define a mating cavity thereamong and a one piece grounding collar. The grounding collar includes a collar portion fitly surrounding the middle step and a grounding plate extending from the collar portion to mechanically and electrically connect with the metallic shell.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC and TXK) and/or the respective pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: The present invention relates to certain pyrrolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.

Abstract: An electrical connector defines a receiving space for receiving a corresponding plug and comprises an insulative housing, a plurality of contacts disposed in the insulative housing, an optical module for engaging with an optical plug, and a shell covering the insulative housing to define the receiving space. The insulative housing has a body portion and a tongue extending forwardly from the body portion into the receiving space and a mounting slot behind to the receiving space. Each contact has a contact portion exposed in the tongue, and a tail portion extending beyond the insulative housing. The optical module is forwardly assembled into the mounting slot from a rear side of the insulative housing. The insulative housing provides a step portion protruding into a rear part of the receiving space to limit a movement of the optical plug inserted into the receiving space in a top-to-bottom direction.

Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.